Noom
Noom is a psychology-based weight loss and wellness app that combines calorie tracking with cognitive behavioral therapy principles. It's designed for people seeking sustainable weight loss through behavior change coaching, personalized meal plans, and support groups.
Score generated by AI agents based on publicly cited evidence and reviewed by the project maintainer. Not independently validated.
Score History
Timeline events are AI-curated from public reporting. Score trajectory is derived from documented events.
Noom found product-market fit by relaunching as a direct-to-consumer CBT-based weight loss subscription app after years of pivoting from fitness hardware and B2B health tools. With CDC recognition for its Diabetes Prevention Program and $12M in revenue, the company offered genuine value through 1-on-1 coaching and behavioral science. Dark patterns and aggressive monetization were minimal at this early stage.
Noom scaled from $12M to $237M in revenue through massive advertising spend that grew from $5M to nearly $50M annually. The auto-renewal subscription model with upfront lump-sum billing and coach-mediated cancellation was now fully operational and generating consumer complaints. Anti-diet marketing language began attracting criticism from eating disorder specialists, and the calorie-restrictive nature of the program started drawing dietitian pushback.
COVID-19 drove revenue from $237M to $400M as locked-down consumers sought home-based weight loss solutions. But the growth came with consequences: a $100M class action lawsuit was filed alleging dark pattern subscription traps, the BBB issued a consumer warning after 1,213 complaints, and TINA.org documented deceptive marketing practices. The company's subscription mechanics were now generating systematic consumer harm at scale.
The $540M Series F at $3.7B valuation represented Noom's apex. Revenue reached $600M, and IPO plans targeted $10B. But Privacy International exposed unauthorized health data sharing, Fast Company documented the co-optation of eating disorder recovery language, and the FTC issued a dark pattern enforcement warning. Noom Mood's launch replicated the same trial-to-subscription model under scrutiny. The gap between public valuation and mounting regulatory exposure was widening.
The $62M class action settlement imposed two years of business practice reforms. But Noom simultaneously gutted its workforce: two rounds of layoffs cut approximately 1,000 employees, nearly halving the coaching team. The CFO departed, IPO plans were shelved, and coaching quality visibly degraded. The B2B 'Noom for Work' launch signaled a shift toward enterprise revenue as consumer growth decelerated.
Co-founder Saeju Jeong was replaced by Geoff Cook as CEO, and a third massive layoff cut approximately 40% of remaining staff. Noom Med launched with branded GLP-1 medications, marking the company's transformation from a behavioral coaching platform to a pharmaceutical intermediary. The 1-on-1 coaching model was formally replaced by anonymous group 'Noom Guides,' completing the degradation of the original value proposition.
Noom has completed its transformation from a mission-driven coaching app to a pharmaceutical monetization platform. The GLP-1 Rx program dominates revenue strategy while the original coaching product continues to degrade. FDA regulatory challenges to compounded semaglutide have prompted aggressive lobbying including a Wall Street Journal ad campaign and HHS petition. Consumer complaints about dark patterns persist despite the 2022 settlement's business practice requirements having expired.
Alternatives
Free calorie and nutrition tracker with no dark patterns or aggressive subscription traps. It tracks macros and micronutrients more precisely than Noom. No coaching component, but the nutrition data is more transparent and useful. Easy switch — just sign up and start logging.
Calorie tracking app with a generous free tier that covers the core use case. Straightforward subscription model without the forced continuity or fake-coach dark patterns Noom settled a class action over. Easy switch — import food history isn't available but starting fresh takes minutes.
What Noom claims to offer but increasingly doesn't: actual human professional guidance on sustainable weight loss. Many accept insurance, and telehealth options have expanded access significantly. More expensive than an app, but you get real expertise rather than an AI chatbot dressed up as a coach.
Dimensional Breakdown
Summaries below were written by AI agents based on the cited evidence. They are editorial interpretations, not independent research findings.
Dimension History
Timeline (40 events)
WorkSmart Labs Rebrands to Noom
The company, originally founded as WorkSmart Labs in 2008 with a stationary-bike accessory, rebranded to Noom and pivoted to weight management. Co-founders Saeju Jeong and Artem Petakov (a former Google engineer) raised a $2.6 million seed round to fund the transition from fitness hardware to mobile health software.
Noom Raises $16M Series B Funding
Noom completed a $16.15 million Series B round led by InterVest, with participation from LB Investment, Hanmi IT, RRE Ventures, TransLink Capital, and Qualcomm Ventures. The funding supported expansion of Noom's mobile preventive health solutions including calorie tracking and coaching features.
Noom Pivots to Direct-to-Consumer Subscription Model
Noom pivoted from its B2B health platform (generating ~$4M/year) to a direct-to-consumer weight loss subscription app. This was the product-market-fit moment, combining WeightWatchers-style coaching with mobile calorie tracking. Revenue grew from $12M ARR in 2017 to over $200M by 2019.
Noom Becomes First Mobile App with CDC DPP Recognition
Noom's Diabetes Prevention Program became the first-ever fully mobile program to receive CDC recognition. A study published in BMJ Open Diabetes Research and Care showed 64% of participants who completed the program lost at least 5% of their body weight. This legitimized Noom's clinical credibility.
Noom Raises $14M Series D from Samsung
Noom completed a $14 million Series D round led by Sampo Holdings. By this point, ad spend had grown from $5M to accelerating levels as Noom scaled its D2C model, with revenue growing rapidly from the 2017 pivot.
Sequoia Capital Leads $58M Series E Round
Noom raised $58 million in Series E funding led by Sequoia Capital, marking the company's largest fundraise at the time. The investment supported expansion of the behavioral coaching model and advertising push that would fuel the pandemic-era growth surge. Revenue was approaching $237M.
Noom Capitalizes on COVID-19 Pandemic Weight Gain
Noom's revenue surged from $237M in 2019 to $400M in 2020 as gym closures and pandemic weight gain drove demand for home-based weight loss solutions. The company offered 'zero cost' trial periods marketed as support during a difficult time, while the class action alleged this exploited consumers amid COVID-19.
$100M Class Action Lawsuit Filed Over Dark Patterns
Geraldine Mahood filed a class action lawsuit in the Southern District of New York seeking $100 million, alleging Noom duped thousands of customers into auto-renewing subscriptions through deceptive trial offers. A former senior software engineer was quoted saying canceling Noom was 'difficult by design.'
Psychology Today Questions Whether Noom Is a Diet
Clinical psychologist and eating disorder specialist Dr. Susan Albers published analysis in Psychology Today concluding Noom is 'most definitely a diet' despite its anti-diet marketing. She warned that calorie counting and daily weigh-ins could trigger eating disorders in vulnerable users.
Truth in Advertising Documents Noom's Deceptive Marketing
Truth in Advertising (TINA.org) documented Noom's deceptive marketing practices, cataloging the ways the company's advertising misrepresented the product. The investigation supported growing public awareness that Noom's marketing claims were inconsistent with the actual user experience.
BBB Issues Consumer Warning After 1,213 Complaints
The Better Business Bureau issued a formal consumer warning about Noom after receiving 1,213 complaints between August 2019 and August 2020. Consumers reported misleading free trials, unexpected charges of $120-$180, and difficulty reaching customer service for refunds. Noom received a 'D' rating from the BBB.
Silver Lake Leads $540M Series F at $3.7B Valuation
Noom raised $540 million in Series F funding led by Silver Lake, with participation from Oak HC/FT, Temasek, Novo Holdings, Sequoia Capital, and Samsung Ventures. The round valued Noom at $3.7 billion, making it a unicorn. The company planned to expand into diabetes, hypertension, and sleep.
Privacy International Exposes Noom's Health Data Sharing
Privacy International's investigation 'An Unhealthy Diet of Targeted Ads' found Noom sharing highly sensitive personal health data (height, weight, medical conditions, dietary restrictions) with multiple third parties including Braze, FullStory, Mixpanel, and Zendesk in real-time, without adequate user consent.
Noom Launches Noom Mood Stress Management App
Noom announced Noom Mood, its first product launch beyond weight management, using CBT, DBT, and mindfulness-based stress reduction. Priced at $149 for four months with a 'pay what you can' trial starting at $0.50, it replicated the same trial-to-subscription dark pattern that had drawn regulatory scrutiny for Noom Weight.
FTC Issues Dark Pattern Enforcement Warning
The FTC issued an enforcement policy statement warning companies against using 'illegal dark patterns that trick or trap consumers into subscription services.' While not naming Noom specifically, the enforcement action directly addressed the subscription practices at the center of Noom's class action lawsuit.
Fast Company Exposes Anti-Diet Language Co-optation
Fast Company published an investigation showing how Noom co-opted the language of eating-disorder recovery communities, using terms like 'anti-diet' and 'mindful eating' to market a calorie-restriction program. Eating disorder specialists warned the marketing directly targeted vulnerable people in recovery. Noom's marketing budget had grown to over $330 million annually.
Noom Plans 2022 IPO at $10B Valuation
Reports emerged that Noom had hired Goldman Sachs to lead preparations for an IPO planned for early 2022, targeting a valuation of nearly $10 billion. This would have been 2.7x the Series F valuation. The company reported approximately $600 million in revenue for 2021.
Noom Proposes $62M Dark Pattern Class Action Settlement
Plaintiffs asked the court to approve a proposed $62 million settlement consisting of $56 million in cash and $6 million in subscription credits. The settlement covered approximately 2 million users who purchased auto-renewing subscriptions between May 2016 and October 2020 and were subjected to deceptive cancellation practices.
Noom Cuts 25% of Coaching Staff in First Layoff
Noom laid off approximately 500 coaches, roughly 25% of its 2,000-person coaching team, as part of what the company called a 'strategy shift' in its coaching model. The cuts moved users from 1-on-1 text-based coaching toward scheduled video-based sessions with higher caseloads per coach.
Court Grants Final Approval of $62M Settlement
A federal judge in the Southern District of New York granted final approval of the $62 million settlement. As part of the terms, Noom agreed to add a cancel button, enhance auto-renewal disclosures, and send email reminders before trial periods expire — business practice changes required for two years.
Second Layoff Cuts 500 More Employees; CFO Departs
Noom laid off approximately 500 more employees (10% of staff), again disproportionately affecting coaches and nearly halving the coaching team to roughly 1,000. CFO Mike Noonan simultaneously departed for Tripadvisor. The company characterized the moves as 'separate, unrelated announcements' while shelving its IPO plans.
Noom Launches B2B Enterprise Offering 'Noom for Work'
Noom debuted its enterprise offering, Noom for Work, at the HLTH conference, bundling Noom Weight, Noom Mood, and the Diabetes Prevention Program for employers and health plans. Over 150 organizations signed up at launch. The B2B pivot signaled a revenue diversification strategy amid slowing consumer growth.
Privacy Lawsuit Filed Over Session Replay Tracking
A class action was filed in Pennsylvania alleging Noom used FullStory's 'session replay' software to record users' mouse movements, clicks, typing, and scrolling in real time without consent, capturing sensitive health information including height, weight, gender, and medical conditions. The case alleged violations of California privacy law.
Privacy International Acknowledges Data Practice Improvements
Privacy International re-tested Noom's data practices and acknowledged 'significant positive changes' since the 2021 investigation. However, the organization noted that data was still being shared with Facebook and concluded 'there is still room for improvement' in privacy protections.
Third Layoff Round Cuts 40% of Remaining Staff
Noom confirmed its third round of layoffs in less than a year, reportedly cutting approximately 40% of the company. The cuts again disproportionately hit coaching and support roles, with employees reporting being blindsided — locked out of systems and notified by email rather than personal communication.
Noom Launches Noom Med Telehealth Program
Noom launched Noom Med, a telehealth program offering branded GLP-1 medications (Ozempic, Mounjaro) combined with behavioral coaching. Available initially in 32 states, the program paired weight loss drugs with Noom's psychological coaching platform. This represented a significant strategic pivot from a behavior-change app to a pharmaceutical intermediary.
Co-Founder CEO Replaced by Geoff Cook
Co-founder Saeju Jeong stepped down as CEO after 16 years, transitioning to Executive Chairman. Geoff Cook, former CEO of The Meet Group (a dating app company he took public on NASDAQ), was appointed as the new CEO. The leadership change signaled a pivot toward enterprise sales, M&A, and GLP-1 monetization.
1-on-1 Coaching Replaced by Anonymous Group 'Noom Guides'
Noom formally transitioned from its signature personalized 1-on-1 coaching model to 'Noom Guides' — unnamed experts answering questions in a group chat format. While still human, the service was significantly depersonalized compared to the original model. 1-on-1 coaching remained available only as a paid add-on for US-based users.
Fourth Round of Layoffs Hits Coaches and Engineers
Noom conducted another round of layoffs in January 2024, cutting coaches and engineering roles as the company shifted resources toward its growing GLP-1 business. The exact number was not disclosed. This marked the fourth round of cuts in less than two years.
Noom Introduces Welli AI Chatbot
Noom officially launched Welli, an AI chatbot positioned to provide 'always-on' coaching for topics like healthy eating while traveling. The company called 2024 'the year of applied AI for Noom.' Users reported difficulty distinguishing AI-generated responses from human coach interactions, echoing the pre-settlement allegations about bot coaches.
Settlement Business Practice Requirements Expire
The two-year period requiring Noom to maintain enhanced auto-renewal disclosures, an easily accessible cancel button, and email reminders before trial periods expire came to an end, per the July 2022 final settlement approval. Consumer complaints about billing practices persisted into 2025-2026.
Noom Relocates Headquarters from NYC to Princeton
Noom moved its headquarters from a 114,000-square-foot space in New York City to a 9,000-square-foot office at One Palmer Square in Princeton, New Jersey — about a year after New Jersey native Geoff Cook became CEO. The downsized office hosts only 20-30 hybrid workers, reflecting the post-layoff workforce.
Noom Launches Compounded GLP-1 Program at $149/Month
Noom launched Noom GLP-1Rx, offering compounded semaglutide at $149/month through FDA-regulated 503B compounding pharmacies. The program included a 'taper-off guarantee' and was paired with behavioral coaching. This was significantly cheaper than branded Wegovy ($1,350/month list) and positioned Noom as a pharmaceutical monetization platform.
Noom Launches Enterprise GLP-1 Management Products
Noom unveiled two new enterprise products: Noom Med with SmartRx (in partnership with Waltz Health) and Noom Weight with GLP-1Rx, designed to help employers manage and control GLP-1 medication expenses. With approximately 250 active B2B partnerships, the launch expanded Noom's pharmaceutical monetization to the enterprise market.
GLP-1 Program Reaches $100M Revenue Run Rate
Noom disclosed that its GLP-1Rx and pill-based medication programs together grew to a $100 million annualized revenue run rate within four months of the September 2024 compounded semaglutide launch. This rapid growth validated the company's pivot from behavioral coaching to pharmaceutical intermediary.
FDA Declares Semaglutide Shortage Resolved
The FDA updated its drug shortage list, declaring the shortage of all doses of injectable semaglutide (Ozempic/Wegovy) resolved. This triggered wind-down deadlines for compounding pharmacies: April 22 for 503A pharmacies and May 22 for 503B facilities. The decision threatened the regulatory basis for Noom's compounded GLP-1 program.
Noom Cuts More Coaches as Healthy Weight Subscriptions Decline
Noom conducted additional layoffs affecting coaching and customer service staff, citing 'a revenue mix shift within the Noom business towards our fast-growing GLP-1-related products.' The company acknowledged that its original Healthy Weight program saw a drop in signups, leaving excess coaching capacity.
Noom Expands into Hormone Replacement Therapy
Noom launched Noom + HRTRx for menopause support, offering FDA-approved transdermal patches and progesterone pills starting at $69/month ($89/month after). The company cited 8 million women aged 40-60 enrolled in Noom programs. The expansion further transformed Noom from a behavioral coaching app into a pharmaceutical distribution platform.
Noom Runs Full-Page WSJ Ad Lobbying for Compounded GLP-1s
Noom published a back-cover advertisement in the Wall Street Journal calling on HHS to create a 'High-Priced Drug List' that would allow compounding pharmacies to produce alternatives to expensive branded drugs even when no shortage exists. The ad included a QR code linking to a public petition directed at HHS.
Noom Launches Microdose GLP-1 Program at $119
Noom launched its Microdose GLP-1Rx program at $119 to start ($199/month after), using doses at 25% or less of the standard maintenance dose. A 2,700-person study showed 16% weight loss over 64 weeks. The program expanded eligibility to BMI 21+, broadening the addressable market beyond clinical obesity.
Evidence (42 citations)
D1: User Value Erosion
D2: Business Customer Exploitation
D3: Shareholder Extraction
D4: Lock-in & Switching Costs
D5: Twiddling & Algorithmic Opacity
D6: Dark Patterns
D7: Advertising & Monetization Pressure
D8: Competitive Conduct
D9: Labor & Governance
D10: Regulatory & Legal Posture
Scoring Log (4 entries)
Added 2 missing dimension narratives
MyFitnessPal is a notable omission but current picks are well-chosen and accurate